Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stemedica Cell Technologies has entered into a collaboration agreement with Lumenis, a medical laser technology firm, to work towards developing a treatment for an eye disease.
Subscribe to our email newsletter
The collaboration will focus on the implementation of a first-of-its-kind, comprehensive clinical study for the treatment of macular degeneration using Stemedica’s MCT (multiple cell technology) adult stem cells and the Lumenis SRT Laser.
The clinical study will be conducted at the Fyodorov Eye Institute in Moscow, Russia. A parallel study will take place at Hospital Angeles, a state-of-the-art hospital located in Tijuana, Mexico. The clinical studies at both Fyodorov Eye Institute and Hospital Angeles will focus on combining stem cell therapy with the use of the Lumenis SRT laser to treat macular degeneration.
Jake Vander Zanden, senior vice president and general manager of Lumenis’s ophthalmic strategic business unit, said: “Together, we believe our clinical study will provide objective clinical evidence that stem cell therapy combined with laser treatment can improve or restore quality of life through better vision.”